Partnership accelerates real-world generative AI value creation in biopharma and medtech industries. SAN FRANCISCO–(BUSINESS WIRE)–#GenAI–Boston Consulting GroupPartnership accelerates real-world generative AI value creation in biopharma and medtech industries. SAN FRANCISCO–(BUSINESS WIRE)–#GenAI–Boston Consulting Group

BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech

Partnership accelerates real-world generative AI value creation in biopharma and medtech industries.

SAN FRANCISCO–(BUSINESS WIRE)–#GenAI–Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of generative AI health care agents. The partnership combines Hippocratic AI’s safety-first technology and health care specialization with BCG’s strategic, operational, and AI transformation expertise to help organizations unlock measurable value across the life sciences value chain.

Despite significant investment in digital technology, BCG benchmarks show that only a small percentage of biopharma and medtech companies are realizing sustained value from AI. This collaboration is designed to close that gap by moving organizations from experimentation to enterprise-scale impact.

A Partnership Built for Impact

Hippocratic AI contributes best-in-class generative AI health care agents, purpose-built for regulated clinical and life sciences environments. With over 150 million clinical interactions to date, these agents support non-diagnostic, patient-facing clinical and operational tasks such as patient onboarding, adherence engagement, clinical trial coordination, and post-market follow-up. Built on Hippocratic AI’s proprietary Polaris Constellation architecture, the agents deliver consistent, safe, empathetic performance that augments human teams.

BCG brings C-suite advisory and AI transformation leadership, including its proprietary Health Care Commercial AI by BCG X offering designed to help health care leaders modernize their commercial models, improve omnichannel engagement, and achieve measurable performance gains. The firm’s insights are supported by ongoing research from BCG X, the tech build and design division of BCG, including benchmark studies and global roundtables focused on AI adoption in biopharma and medtech.

“This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI’s sophisticated AI agent platform, BCG’s strategy and governance expertise, and BCG X’s Health Care Commercial AI solution to help clients turn potential into measurable business value,” said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X.

“Our collaboration with BCG is built on a shared commitment to improving patient outcomes,” said Munjal Shah, Founder and CEO of Hippocratic AI. “By combining BCG’s deep strategic and operational expertise with our safety-focused generative AI health care agents, we can accelerate innovation across biopharma and medtech, bringing scalable, empathetic, and clinically aligned support to patients, providers, and researchers around the world.”

About Hippocratic AI

Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient and HCP facing clinical AI agents that do not prescribe or diagnose. Its proprietary Polaris Constellation architecture ensures accuracy, alignment, and safety in regulated healthcare and life-sciences settings. Since 2023, the company has raised a total of $404 million backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA’s NVentures, Premji Invest, SV Angel, Google’s CapitalG, and numerous health systems. The company partners with more than 50 health systems, payers, and life-sciences organizations worldwide.

https://hippocraticai.com/

About Boston Consulting Group

Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we help clients embrace transformation to benefit all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.

Our diverse global teams bring deep industry expertise and a range of perspectives that spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and digital ventures. We work collaboratively across the firm and with our clients to help them thrive and make the world a better place.

Learn more at www.bcg.com and explore insights from BCG X.

Contacts

Media contacts:
BCG: Eric Gregoire – gregoire.eric@bcg.com
Hippocratic AI: Rick Keating – press@hippocraticai.com

Market Opportunity
Sleepless AI Logo
Sleepless AI Price(AI)
$0.04238
$0.04238$0.04238
+0.92%
USD
Sleepless AI (AI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44
China Bans Nvidia’s RTX Pro 6000D Chip Amid AI Hardware Push

China Bans Nvidia’s RTX Pro 6000D Chip Amid AI Hardware Push

TLDR China instructs major firms to cancel orders for Nvidia’s RTX Pro 6000D chip. Nvidia shares drop 1.5% after China’s ban on key AI hardware. China accelerates development of domestic AI chips, reducing U.S. tech reliance. Crypto and AI sectors may seek alternatives due to limited Nvidia access in China. China has taken a bold [...] The post China Bans Nvidia’s RTX Pro 6000D Chip Amid AI Hardware Push appeared first on CoinCentral.
Share
Coincentral2025/09/18 01:09
Pi Network News: New Developments Could Push Price to $0.40

Pi Network News: New Developments Could Push Price to $0.40

Analysts highlight new Pi Network developments that could lift its price toward $0.40 in 2025.
Share
Blockchainreporter2025/09/18 07:59